Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen’s Q3 Aduhelm Sales Even Worse Than Expected

Executives Emphasize Low Expectations Through Year-End

Executive Summary

Analysts expected at least $12m in third quarter sales, but the Alzheimer’s therapy brought in just $300,000. The company says educating doctors and procuring a coverage determination from CMS – not lower pricing – are key to growth.  

You may also be interested in...



Biogen Resets Aduhelm Expectations, Expects Longer, Slower Path To Significant Sales

The company reported $1m in Q4 sales of its Alzheimer’s drug. Biogen expects Aduhelm to make a minimal contribution to full-year 2022 revenues, which will total about $1bn less than in 2021. 

Lilly Braces For Impact Of CMS Draft Coverage Decision On Biogen’s Aduhelm

The draft national coverage determination, released shortly before Lilly CEO David Ricks spoke at the J.P. Morgan Healthcare Conference, said Medicare will cover anti-amyloid antibodies only for patients in clinical trials, severely limiting commercial potential for Biogen’s Aduhelm and near-term competitors.

J.P. Morgan Day 1: Pharma Execs Offer Big Talk Instead Of Big Deals

Daily notebook from the virtual J.P. Morgan Healthcare Conference: business development is top of mind for BMS, Merck, J&J and Pfizer, while Novartis, Moderna and Regeneron talk about next steps. Bayer looks to minimize Xarelto patent expiry, a new chief exec debuts for Alnylam and EY suggests 2022 will be another year of bolt-on deals. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel